New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi's existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.

Curi Bio's preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi's suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues-with a focus on cardiac, musculoskeletal, and neuromuscular models-for the discovery, safety testing, and efficacy testing of new drugs in development. The company's proprietary technologies are supported by over 100 publications and 19 patents. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.